Philip Ambery (Phil Ambery)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Chronic Kidney Disease

Top Venues

Diabetes, obesity & metabolism

British journal of clinical pharmacology

Clinical science (London, England : 1979)

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology (2024)
Rajna Golubic, Jane Kennet, Victoria E R Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Philip Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark L Evans
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes, obesity & metabolism 26 (7) (2024)
Philip Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? Clinical science (London, England : 1979) 138 (11) (2024)
Philip Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? Clinical science (London, England : 1979) 138 (11) (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics 116 (3) (2024)
Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology 90 (8) (2024)
Rajna Golubic, Jane Kennet, Victoria E R Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Philip Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark L Evans
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes, obesity & metabolism 26 (7) (2024)
J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, Jose Luis Gorriz Teruel, Maria José Soler, Magnus Åstrand, Anne-Kristina Mercier, Peter J Greasley, Philip Ambery, Hiddo J Lambers Heerspink
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD. Journal of the American Society of Nephrology : JASN (2024)
Rajna Golubic, Jane Kennet, Victoria E R Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Philip Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark L Evans
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes, obesity & metabolism (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics (2024)
Victoria E R Parker, Darren Robertson, Edmundo Erazo-Tapia, Bas Havekes, Esther Phielix, Marlies de Ligt, Kay H M Roumans, Julian Mevenkamp, Folke Sjoberg, Vera B Schrauwen-Hinderling, Edvin Johansson, Yi-Ting Chang, Russell Esterline, Kenneth Smith, Daniel J Wilkinson, Lars Hansen, Lars Johansson, Philip Ambery, Lutz Jermutus, Patrick Schrauwen
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nature metabolism (2023)
Victoria E R Parker, Thuong Hoang, Heike Schlichthaar, Fraser W Gibb, Barbara Wenzel, Maximillian G Posch, Ludger Rose, Yi-Ting Chang, Marcella Petrone, Lars Hansen, Philip Ambery, Lutz Jermutus, Hiddo J Lambers Heerspink, Rory J McCrimmon
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes, obesity & metabolism 24 (7) (2022)
Philip Ambery, Samuel Adamsson Eryd, Sara Jenkins-Jones, Ben Heywood, Ellen Berni, Mary N Brown, Carol Astbury, Phillip Hunt, Craig J Currie
The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups. Diabetes, obesity & metabolism 24 (11) (2022)
Michiko Asano, Akiko Sekikawa, Hyosung Kim, Robert A Gasser, Darren Robertson, Marcella Petrone, Lutz Jermutus, Philip Ambery
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes. Diabetes, obesity & metabolism 23 (8) (2021)